Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa C LynceCandace MainorRenee N DonahueXue GengGreg JonesIlana SchlamHongkun WangNicole J ToneyCaroline JochemsJeffrey SchlomJay ZeckChristopher M GallagherRita NandaDeena GrahamErica M Stringer-ReasorNeelima DenduluriJulie M CollinsAmi ChitaliaShruti TiwariRaquel A NunesRebecca KaltmanKatia KhouryMargaret Gatti-MaysPaolo TarantinoSara M TolaneySandra M SwainPaula PohlmannHeather A ParsonsClaudine IsaacsPublished in: Nature communications (2024)